Table 3.

Effect of recalculation of eGFR using the 2021 Chronic Kidney Disease Epidemiology Collaboration creatinine concentration equation among randomized participants in the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial

VariableOriginalRecalculated (2021 Chronic Kidney Disease Epidemiology Collaboration)DifferenceNet Change Total No. (%)
Randomized individuals (overall)
 n44014397
 Screening eGFR, ml/min per 1.73 m2, mean (SD)a56 (16)60 (18)
  Screening eGFR group, no. (%)P<0.001
   eGFR≥900301 (7)301 (7)
   eGFR≥60 to <901820 (41)1768 (40)−52 (−1)
   eGFR≥45 to <601276 (29)1233 (28)−43 (−1)
   eGFR≥30 to <451301 (30)1057 (24)−244 (−6)
   eGFR<30038 (0.9)38 (0.9)
  eGFR≥90 or eGFR<30, ml/min per 1.73 m2, no. (%)0339 (8)339 (8)
Randomized individuals (non-Black)
 n41774174
 Screening eGFR, ml/min per 1.73 m2, mean (SD)a56 (17)60 (18)
  Screening eGFR group, no. (%)P<0.001
   eGFR≥900300 (7)300 (7)
   eGFR≥60 to <901731 (41)1699 (41)−32 (−0.8)
   eGFR≥45 to <601204 (29)1154 (28)−50 (−1)
   eGFR≥30 to <451239 (30)991 (24)−248 (−6)
   eGFR<30030 (0.7)30 (0.7)
  eGFR≥90 or eGFR<30, ml/min per 1.73 m2, no. (%)0330 (8)
Randomized individuals (Black)
 n224223
 Screening eGFR, ml/min per 1.73 m2, mean (SD)a56 (16)52 (15)
  Screening eGFR group, no. (%)P<0.001
   eGFR≥9001 (0.4)1 (0.4)
   eGFR≥60 to <9089 (40)69 (31)−20 (−9)
   eGFR≥45 to <6073 (33)79 (35)7 (3)
   eGFR≥30 to <4562 (28)66 (30)4 (2)
   eGFR<3008 (4)8 (4)
  eGFR≥90 or eGFR<30, ml/min per 1.73 m2, no. (%)09 (4)9 (4)
  • a Means (SDs) were calculated as per 4397 randomized participants (4174 for non-Black and for 223 Black) with available data for screening serum creatinine.